Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
About
Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient population in endocrinology, neurology, and gastroenterology. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.
Xeris is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005146/en/
Investor Contact
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: